Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Paula Vainio 1 , Laura Lehtinen 1 , Tuomas Mirtti 2,3,4 , Mika Hilvo 5 , Tuulikki Seppänen-Laakso 5 , Johannes Virtanen 1 , Anna Sankila 4 , Stig Nordling 4 , Johan Lundin 3 , Antti Rannikko 6 , Matej Orešič 5 , Olli Kallioniemi 1,3 and Kristiina Iljin 1 1 Medical Biotechnology, VTT Technical Research Centre of Finland, and Turku Centre for Biotechnology, University of Turku, Finland 2 Haartman Institute, Department of Pathology, University of Helsinki, Finland 3 Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Finland 4 HUSLAB, Department of Pathology, Helsinki University Central Hospital, Finland 5 Bio and Process Technology, VTT Technical Research Centre of Finland, Espoo, Finland 6 Department of Urology, Helsinki University Central Hospital, Finland Received: December 20, 2011; Accepted: December 22, 2011; Published: December 22, 2011; Keywords: Prostate cancer, PLA2G7, drug target, biomarker, statins Correspondence: Kristiina Iljin, email: // // Abstract Prostate cancer is the second leading cause of cancer mortality in men in developed countries. Due to the heterogeneous nature of the disease, design of novel personalized treatments is required to achieve efficient therapeutic responses. We have recently identified phospholipase 2 group VII ( PLA2G7 ) as a potential drug target especially in ERG oncogene positive prostate cancers. Here, the expression profile of PLA2G7 was studied in 1137 prostate cancer and 409 adjacent non-malignant prostate tissues using immunohistochemistry to validate its biomarker potential and putative association with disease progression. In order to reveal the molecular alterations induced by PLA2G7 impairment, lipidomic and gene expression profiling was performed in response to PLA2G7 silencing in cultured prostate cancer cells. Moreover, the antineoplastic effect of statins combined with PLA2G7 impairment was studied in prostate cancer cells to evaluate the potential of repositioning of in vivo compatible drugs developed for other indications towards anti-cancer purposes. The results indicated that PLA2G7 is a cancer-selective biomarker in 50 % of prostate cancers and associates with aggressive disease. The alterations induced by PLA2G7 silencing highlighted the potential of PLA2G7 inhibition as an anti-proliferative, pro-apoptotic and anti-migratorial therapeutic approach in prostate cancer. Moreover, the anti-proliferative effect of PLA2G7 silencing was potentiated by lipid-lowering statins in prostate cancer cells. Taken together, our results support the potential of PLA2G7 as a biomarker and a drug target in prostate cancer and present a rationale for combining PLA2G7 inhibition with the use of statins in prostate cancer management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Härmä, V., Virtanen, J., Mäkelä, R., Happonen, A., Mpindi, J.-P., Knuuttila, M., Kohonen, P., Lötjönen, J., Kallioniemi, O., & Nees, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010431 · Cited by 344
Self-citationZong, Y., Xin, L., Goldstein, A. S., Lawson, D. A., Teitell, M. A., & Witte, O. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905931106 · Cited by 203 · cited 1×
“Ectopic expression of the most frequent fusion partner, ERG (v-ets erythroblastosis virus E26 oncogene homolog, avian), promotes multiple signaling pathways associated with cancer formation and progression [3-7].”
Cited by
Lipoprotein‐associated phospholipase A2: The story continues
Huang, F., Wang, K., & Shen, J. (2020) · Medicinal Research Reviews · doi:10.1002/med.21597 · Cited by 212
“PLA2G7 expression produced antiproliferative, proapoptotic, and antimigratory effects on prostate cancer cells and that statin treatment combined with PLA2G7 silencing synergistically exerted an antiproliferative effect.(197) Recently, Alinezhad et al(198) also identified PLA2G7 as a valid biomarker for prostate cance…”
BackgroundIdentification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma
Zheng, W., Lin, Q., Issah, M. A., Liao, Z., & Shen, J. (2021) · BMC Cancer · doi:10.1186/s12885-021-08660-4 · Cited by 21
Wang, Y.-J., Chang, S.-B., Wang, C.-Y., Huang, H.-T., & Tzeng, S.-F. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115133 · Cited by 12
Metadata
- Authors
- Vainio, P., Lehtinen, L., Mirtti, T., Hilvo, M., Seppänen-Laakso, T., Virtanen, J., Sankila, A., Nordling, S., Lundin, J., Rannikko, A., Orešič, M., Kallioniemi, O., & Iljin, K.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2011-12-22
- Volume
- 2
- Issue
- 12
- Pages
- 1176-1190
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1525585340
- Cited by
- 96
- References
- 3
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. https://app.cochat.ai/papers/10.18632/oncotarget.397
- The paper
- Vainio, P., Lehtinen, L., Mirtti, T., Hilvo, M., Seppänen-Laakso, T., Virtanen, J., Sankila, A., Nordling, S., Lundin, J., Rannikko, A., Orešič, M., Kallioniemi, O., & Iljin, K. (2011). Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget. https://doi.org/10.18632/oncotarget.397
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.